Kailera Therapeutics

Today, we reported financial results for the second quarter of 2026 and provided a summary of recent pipeline and corporate updates. Highlights include: - IND for ribupatide oral active with U.S. FDA, initiation of global Phase 3 obesity trials planned for the first half of 2027 - Ribupatide injection Phase 2b high-dose trial in obesity fully enrolled, data anticipated in mid-2027 - Expanded executive team to strengthen technical operations capabilities and corporate affairs leadership - Cash, cash equivalents, and marketable securities expected to support execution of multiple clinical milestones with runway into mid-2028 With continued momentum across our business and pipeline, we remain focused on advancing therapies that have the potential to maximize weight loss, improve tolerability, and address other critical needs for people living with obesity and overweight. Read the full earnings announcement here: https://lnkd.in/eEMGkdkU #Obesity #ObesityCare #GLP1 #WeightManagement #KaileraTx

Today we announced Nur Nicholson as Chief Technology Officer of Kailera. Nur's expertise in building resilient, scalable manufacturing networks will be key to delivering on our mission for people living with obesity. Please join us in welcoming Nur to the team! Read the press release here: https://lnkd.in/eaNyEU-u #KaiCrew #KaileraTx

Happy #NationalInternDay to our incredible summer interns! Over the past few months, our interns have brought fresh perspectives, curiosity, and enthusiasm to the team while making meaningful contributions across the company. This summer, they’ve been involved in a wide range of initiatives – from supporting clinical trial activities and patient safety operations to contributing to strategic business projects, market insights, and cross-functional collaboration efforts that help advance our mission of improving the lives of people living with obesity. We’re grateful for the energy, creativity, and dedication they’ve brought to Kailera. It’s been exciting to watch them jump in, ask thoughtful questions, and take on projects that are helping move our work forward! #KaiCrew #KaileraLife #FutureLeaders #KaileraTx

The Kailera team had a great experience at #YWM2026! We’re grateful to the Obesity Action Coalition for bringing together such a powerful and supportive community. At Kailera, we’re focused on elevating the next era of #obesitycare, and we’re proud to stand alongside patients, advocates, and healthcare leaders working to improve understanding and support for people living with #obesity.

Excited to be attending and sponsoring the Obesity Action Coalition’s #YWM2026 National Convention this week where we’re looking forward to productive conversations and meaningful learning opportunities from leading #obesitycare experts!      At Kailera, we’re proud to support communities that foster deeper understanding and reduce stigma in #obesity. We hope to see you there! #YourWeightMatters #KaileraTx 

Behind every milestone is a team united by a shared purpose and a commitment to making a meaningful impact. At Kailera, our continued growth and success are driven by the individuals who bring passion, expertise, and excellence to everything they do.    This month’s KaiLeader is Corey Manchester, Vice President, Corporate Controller.    “In my role as Kailera’s Corporate Controller, I oversee the talented and dedicated accounting team. As we’ve transitioned to operating as a public company, building a strong foundation of trust and transparency has been paramount. We are highly collaborative, working closely with teams across the organization to navigate complex transactions, support strategic decisions, and ensure we’re aligned in a fast-paced environment. We demonstrate commitment through a persistent focus on accuracy and integrity. I am proud of the team we’ve built and truly believe our collaboration and commitment will help support Kailera’s impact on patients’ lives.”    #KaiLeaders #KaiCrew #KaileraTx 

What does it look like to help build a company from the ground up? Our SVP of Clinical Development Operations, Manny Lazaro, shares his journey from joining Kailera as employee #5 to helping grow a team focused on advancing late-stage global clinical programs with one shared purpose: bringing potential new treatment options to patients living with obesity. Manny talks about what inspired him to join Kailera, what makes our culture unique, and why this is such an exciting time to be part of our Clinical Development Operations and Data Management team. If you’re looking for the opportunity to make a meaningful impact, collaborate with exceptional colleagues, and help shape the future of our growing company, we’d love to hear from you! Explore our open opportunities here: https://lnkd.in/gGxQV7_S #Hiring #BiotechCareers #KaiCrew #KaileraTx

Kailera recently welcomed Faith Anne Heeren, PhD, a postdoctoral fellow at Wake Forest University School of Medicine and dedicated obesity patient advocate, for a virtual fireside chat with our team.    Drawing from both her professional expertise and personal journey, Dr. Heeren shared a powerful perspective on the realities of living with obesity. She spoke candidly about the challenges individuals face every day – from stigma and misconceptions to navigating treatment and care her whole life – and highlighted why listening to and learning from lived experiences is essential to advancing obesity care.    Dr. Heeren’s passion for advocacy began after undergoing gastric bypass surgery at age 16 and has since led her to become a leading voice for patients through research, education, and organizations such as the Obesity Action Coalition and OCEANS. Her thoughtful discussion and open Q&A challenged us to think differently, deepen our empathy, and reaffirm the importance of keeping patients at the center of everything we do.    We’re grateful to Dr. Heeren for sharing her time, experiences, and insights with our team. Conversations like these reinforce Kailera’s commitment to advancing differentiated treatment options for obesity while never losing sight of the individuals we aim to serve.    #KaileraTx #KaiCrew #ObesityCare #Obesity #PatientAdvocacy

Kailera today announced positive topline data from two Hengrui Pharma Phase 3 clinical trials of HRS-7535/KAI-7535, a GLP-1receptor agonist oral small molecule.    These Phase 3 results in obesity/overweight and type 2 diabetes highlight the promise of oral small molecules as a treatment option for people living with obesity. Kailera is currently advancing KAI-7535 in a global Phase 2 designed to further optimize its clinical profile for the treatment of obesity, with data expected in 2027.    Together with our other clinical stage programs, KAI-7535 reflects our strategy of advancing a diversified portfolio across multiple mechanisms and modalities to meet the evolving and diverse needs of people living with obesity.    Read the full press release here: https://lnkd.in/gSAHzhMC   #Obesity #ObesityCare #GLP1 #WeightManagement #KaileraTx 

Giving back to our communities is one of the many ways we live our values at Kailera.     This month, members of our Regulatory Affairs and Quality teams volunteered with Room to Grow, an organization that supports parents and caregivers with essential resources, developmental guidance, and community connections to help children thrive.     Together, our team assembled 90 bundles of children’s books that will help foster learning, imagination, and early childhood development for families in need.     Thank you to everyone who participated in this meaningful effort and to Life Science Cares Boston for helping us organize this opportunity. We’re proud to support our local organizations making a lasting difference in the lives of children and families!     #KaileraCares #CommunityImpact #GivingBack #KaiValues #KaiCrew